Legacy Capital Group California Inc. Makes New $1.33 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN

Legacy Capital Group California Inc. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, Holdings Channel.com reports. The fund acquired 1,716 shares of the biopharmaceutical company’s stock, valued at approximately $1,325,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Salomon & Ludwin LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $27,000. Board of the Pension Protection Fund bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth $31,000. Caitlin John LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $34,000. FNY Investment Advisers LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $38,000. Finally, E Fund Management Hong Kong Co. Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 87.5% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 35 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. This represents a 32.28% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 3,774 shares of company stock valued at $2,942,738. 7.02% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $751.23 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The company’s 50-day moving average is $764.22 and its 200 day moving average is $729.68. The stock has a market capitalization of $79.42 billion, a P/E ratio of 17.96, a P/E/G ratio of 1.66 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter last year, the firm earned $12.07 earnings per share. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.2 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

Analyst Ratings Changes

REGN has been the subject of a number of research reports. Sanford C. Bernstein cut their target price on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. Morgan Stanley increased their price objective on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Guggenheim boosted their price target on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Zacks Research downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Finally, JPMorgan Chase & Co. upped their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $811.96.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.